Skip to main content

What the FDA labels say about taking them together

Pretomanid and rifampin

Pretomanid's FDA label of November 15, 2024 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name pretomanid. The pretomanid label: “Strong or moderate CYP3A4 inducers such as rifampin or efavirenz: Avoid co-administration.”

Check it at the source: the pretomanid FDA label on DailyMed (effective November 15, 2024, Viatris Specialty LLC); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).

What does the pretomanid label say about rifampin?

Pretomanid label, drug interactions

Strong or moderate CYP3A4 inducers such as rifampin or efavirenz: Avoid co-administration.

Pretomanid label, warnings and precautions

Avoid co‑administration of strong or moderate CYP3A4 inducers, such as rifampin or efavirenz, during treatment with pretomanid.

Source: FDA drug label (Pretomanid), NDA212862 (Mylan Ireland Ltd), as published by Viatris Specialty LLC, effective November 15, 2024 (SPL set f1906fc9-cb3c-4e13-8a4a-da76100c1bf3), via openFDA; the full label on DailyMed

What does the rifampin label say about pretomanid?

Rifampin's label (effective February 11, 2026) does not name pretomanid in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Pretomanid generic labelers
13Rifampin generic labelers
PretomanidRifampin
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.679 per capsule 300 mg capsule
Shortage nowNo current entryIn shortage

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?